ADPT

Adaptive Biotechnologies Corp (ADPT) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Adaptive Biotechnologies is a commercial-stage company advancing immune medicine through its Minimal Residual Disease (MRD) and Immune Medicine business areas. Key products include the clonoSEQ diagnostic test and the Adaptive Immunosequencing research platform. The company operates under a significant collaboration agreement with Genentech for the development of T-cell therapies.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 36% year-over-year in Q2 2025. MRD revenue grew 42% to $49.9 million, driven by a 37% increase in clonoSEQ test volume (25,321 tests) and $5.5 million in regulatory milestone revenue. Immune Medicine revenue grew 13% to $8.9 million, primarily due to increased collaboration revenue from Genentech.
• Expense Reduction: Operating expenses decreased significantly compared to the prior year. Research and Development (R&D) expenses fell 5% to $24.1 million, and Cost of Revenue decreased 7% to $18.0 million due to reduced inventory reserves and laboratory consolidation efficiencies.
• Impairment Charges: Unlike Q2 2024, which included a $7.2 million impairment charge for long-lived assets and leasehold improvements, Q2 2025 had no impairment charges.
• Profitability Improvement: The net loss narrowed substantially from $46.2 million in Q2 2024 to $25.6 million in Q2 2025. Adjusted EBITDA improved from a deficit of $21.4 million to $7.2 million.

Guidance, Outlook, and Risks

• Liquidity: The company holds $222.0 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
• Revenue Interest Agreement: The company has a revenue interest purchase agreement with OrbiMed. It received $125.0 million initially and is entitled to up to an additional $125.0 million in installments (subject to conditions) by September 12, 2025. The effective interest rate on this liability was 8.9% as of June 30, 2025.
• Outlook: Management expects MRD revenue to increase long-term through expanded patient populations and payor coverage. Immune Medicine revenue is expected to grow as therapies advance toward commercialization. Sales and marketing expenses are expected to increase in the short term to drive adoption.
• Risks: Key risks include reliance on collaborators (Genentech) for development and commercialization, uncertainty in reimbursement rates for clonoSEQ, and the potential for future restructuring or impairment charges if development timelines shift.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 37% increase in clonoSEQ test volume and the timing of the $5.5 million regulatory milestone revenue recognized in Q2.
• Genentech Collaboration: Review the status of the Genentech agreement, specifically the recognition of collaboration revenue ($3.9M in Q2) and the remaining potential milestones ($1.8 billion total potential).
• Debt Obligations: Confirm the terms and potential drawdown dates for the remaining $125 million available under the OrbiMed Revenue Interest Purchase Agreement.
• Cost Structure: Assess whether the reduction in R&D and Cost of Revenue is a one-time benefit from restructuring/consolidation or a sustainable trend.
• Share-Based Compensation: Note that share-based compensation remains a significant non-cash expense ($13.4M in Q2), impacting GAAP net loss but excluded from Adjusted EBITDA.